Exact Sciences Stock Price Target and Analyst Ratings (NASDAQ:EXAS)

Analyst Price Target for EXAS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$145.31

▲ +7.78% Upside Potential

This price target is based on 15 analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is $145.31, with a high forecast of $226.00 and a low forecast of $70.00. The average price target represents a 7.78% upside from the last price of $134.82.

Buy

The current consensus among 15 investment analysts is to buy stock in Exact Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
10 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

9/3/2019

0 strong buy ratings
13 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

12/2/2019

0 strong buy ratings
14 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

3/1/2020

0 strong buy ratings
15 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

5/30/2020

0 strong buy ratings
14 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

8/28/2020

0 strong buy ratings
12 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

11/26/2020

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

1/25/2021

0 strong buy ratings
12 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

2/24/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
2/18/2021	Robert W. Baird	Lower Price Target	Outperform	$169.00 ➝ $163.00	Low	i
2/17/2021	Stifel Nicolaus	Boost Price Target	Buy	$150.00 ➝ $165.00	Low	i
2/17/2021	SVB Leerink	Boost Price Target	Market Perform ➝ Outperform	$170.00 ➝ $180.00	Low	i Rating by P. Souda at SVB Leerink LLC
2/17/2021	Cowen	Boost Price Target	Outperform	$154.00 ➝ $180.00	Low	i
1/27/2021	Truist	Initiated Coverage	Buy	$226.00 ➝ $226.00	Medium	i
1/21/2021	SVB Leerink	Boost Price Target	Outperform	$160.00 ➝ $170.00	Medium	i Rating by P. Souda at SVB Leerink LLC
1/12/2021	Canaccord Genuity	Boost Price Target	Buy	$160.00 ➝ $165.00	Low	i
10/29/2020	UBS Group	Downgrade	Buy ➝ Neutral	$125.00 ➝ $140.00	High	i
10/28/2020	Canaccord Genuity	Boost Price Target	Buy	$120.00 ➝ $145.00	Low	i
10/28/2020	Oppenheimer	Boost Price Target		$115.00 ➝ $150.00	Low	i
10/28/2020	BTIG Research	Boost Price Target		$140.00 ➝ $155.00	Low	i
10/28/2020	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral	$120.00 ➝ $140.00	Low	i
10/28/2020	Robert W. Baird	Boost Price Target	Positive ➝ Outperform	$135.00 ➝ $150.00	Low	i
10/28/2020	SVB Leerink	Boost Price Target	Outperform	$115.00 ➝ $160.00	Low	i
10/28/2020	Benchmark	Boost Price Target	Buy	$110.00 ➝ $145.00	Low	i
10/28/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Downgrade	Buy ➝ Neutral	$120.00 ➝ $140.00	Medium	i
9/25/2020	Canaccord Genuity	Boost Price Target	Buy	$115.00 ➝ $120.00	Low	i
7/31/2020	SVB Leerink	Boost Price Target	Outperform	$90.00 ➝ $115.00	High	i
7/31/2020	Benchmark	Boost Price Target	Buy	$90.00 ➝ $110.00	Low	i
7/31/2020	Citigroup	Boost Price Target	Buy	$110.00 ➝ $120.00	Low	i
7/8/2020	Oppenheimer	Reiterated Rating	Buy		High	i Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
6/25/2020	Citigroup	Boost Price Target	Buy	$100.00 ➝ $110.00	Medium	i
5/7/2020	Robert W. Baird	Boost Price Target	Outperform	$90.00 ➝ $92.00	Low	i Rating by Catherine Ramsey Schulte at Robert W. Baird
5/7/2020	Bank of America	Boost Price Target	Buy	$88.00 ➝ $94.00	Low	i
5/7/2020	Craig Hallum	Lower Price Target	In-Line ➝ Buy	$99.00 ➝ $92.00	Low	i
5/7/2020	Canaccord Genuity	Lower Price Target	Buy	$120.00 ➝ $110.00	High	i Rating by Max Masucci at Canaccord Genuity
5/7/2020	SVB Leerink	Lower Price Target	Outperform	$100.00 ➝ $90.00	High	i
4/28/2020	UBS Group	Lower Price Target	Buy	$135.00 ➝ $115.00	High	i
4/22/2020	Citigroup	Lower Price Target	Buy	$120.00 ➝ $100.00	Medium	i
4/22/2020	Robert W. Baird	Lower Price Target	Outperform	$100.00 ➝ $90.00	High	i Rating by Catherine Ramsey Schulte at Robert W. Baird
4/21/2020	Oppenheimer	Reiterated Rating	Buy	$115.00	Low	i
4/17/2020	Craig Hallum	Lower Price Target	Buy	$127.00 ➝ $99.00	High	i
4/2/2020	Stifel Nicolaus	Lower Price Target	Buy	$110.00 ➝ $90.00	Low	i Rating by Daniel Arias at Stifel Nicolaus
4/2/2020	Evercore ISI	Initiated Coverage	Outperform	$70.00	High	i
2/14/2020	Stifel Nicolaus	Reiterated Rating	Buy	$110.00	N/A	i Rating by Daniel Arias at Stifel Nicolaus
2/12/2020	Robert W. Baird	Reiterated Rating	Buy		Low	i Rating by Catherine Ramsey Schulte at Robert W. Baird
2/12/2020	Canaccord Genuity	Reiterated Rating	Buy	$120.00	High	i Rating by Max Masucci at Canaccord Genuity
2/6/2020	Canaccord Genuity	Reiterated Rating	Buy	$120.00	Low	i Rating by Max Masucci at Canaccord Genuity
1/10/2020	BTIG Research	Initiated Coverage	Buy	$127.00	High	i Rating by Amanda Murphy at BTIG Research
1/6/2020	Citigroup	Initiated Coverage	Buy	$120.00	Low	i
12/13/2019	Dougherty & Co	Initiated Coverage	Buy	$120.00	Low	i Rating by K. Bauser at Dougherty & Co
11/14/2019	Stifel Nicolaus	Initiated Coverage	Buy	$110.00	High	i
10/31/2019	Bank of America	Reiterated Rating	Buy	$135.00	Medium	i
10/30/2019	SVB Leerink	Lower Price Target	Outperform	$133.00 ➝ $105.00	Medium	i Rating by Puneet Souda at SVB Leerink LLC
10/30/2019	Canaccord Genuity	Lower Price Target	Buy	$135.00 ➝ $120.00	High	i Rating by Mark Massaro at Canaccord Genuity
10/30/2019	Jefferies Financial Group	Lower Price Target	Buy	$138.00 ➝ $120.00	High	i
10/17/2019	Bank of America	Boost Price Target	Buy	$130.00 ➝ $135.00	Low	i
9/26/2019	Oppenheimer	Initiated Coverage	Outperform	$130.00	Medium	i
9/24/2019	SVB Leerink	Reiterated Rating	Buy		High	i Rating by Puneet Souda at SVB Leerink LLC
9/23/2019	Benchmark	Upgrade	Hold ➝ Buy	$130.00	High	i
9/10/2019	William Blair	Reiterated Rating	Buy		Low	i Rating by Brian Weinstein at William Blair
9/10/2019	Canaccord Genuity	Reiterated Rating	Buy	$135.00	Low	i
8/1/2019	UBS Group	Boost Price Target	Buy	$120.00 ➝ $143.00	Low	i Rating by Daniel Brennan at UBS Group AG
7/30/2019	Craig Hallum	Boost Price Target	Buy	$115.00 ➝ $127.00	Medium	i Rating by Per Ostlund at Craig Hallum
7/29/2019	Cowen	Boost Price Target	Outperform	$125.00 ➝ $135.00	Low	i
7/17/2019	Canaccord Genuity	Reiterated Rating	Buy	$118.00 ➝ $125.00	Low	i
5/1/2019	Jefferies Financial Group	Boost Price Target	Buy	$100.00 ➝ $115.00	Low	i
5/1/2019	UBS Group	Boost Price Target	Buy ➝ Buy	$115.00 ➝ $120.00	Low	i Rating by Daniel Brennan at UBS Group AG
5/1/2019	Craig Hallum	Reiterated Rating	Buy	$95.00 ➝ $115.00	Low	i Rating by Per Ostlund at Craig Hallum
5/1/2019	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $110.00	Medium	i
5/1/2019	BTIG Research	Boost Price Target	Buy	$130.00	Low	i
4/16/2019	UBS Group	Boost Price Target	Buy ➝ Buy	$109.00 ➝ $115.00	Low	i Rating by Daniel Brennan at UBS Group AG
2/26/2019	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$85.00 ➝ $120.00	Medium	i
2/22/2019	UBS Group	Set Price Target	Buy	$109.00	Low	i Rating by Daniel Brennan at UBS Group AG
2/22/2019	Craig Hallum	Set Price Target	In-Line ➝ Buy	$77.00 ➝ $95.00	High	i
2/22/2019	BTIG Research	Boost Price Target	Buy ➝ Positive	$110.00	High	i
2/21/2019	Robert W. Baird	Boost Price Target	Outperform	$90.00 ➝ $102.00	High	i
1/28/2019	UBS Group	Boost Price Target	Buy	$100.00 ➝ $109.00	Medium	i Rating by Daniel Brennan at UBS Group AG
1/14/2019	Canaccord Genuity	Boost Price Target	Buy	$87.00 ➝ $95.00	High	i
1/7/2019	William Blair	Reiterated Rating	Outperform		High	i
11/29/2018	UBS Group	Set Price Target	Buy	$100.00	Low	i Rating by Daniel Brennan at UBS Group AG
10/31/2018	Jefferies Financial Group	Boost Price Target	Buy ➝ Buy	$74.00 ➝ $84.00	Low	i
10/30/2018	UBS Group	Set Price Target	Buy	$100.00	High	i Rating by Daniel Brennan at UBS Group AG
10/9/2018	UBS Group	Initiated Coverage	Buy ➝ Buy	$100.00	Low	i
9/12/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$72.00 ➝ $87.00	Low	i
9/11/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$74.00 ➝ $85.00	Low	i
9/6/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$68.00 ➝ $92.00	Medium	i Rating by Derik De Bruin at Bank of America Co.
9/5/2018	Cowen	Boost Price Target	Outperform	$65.00 ➝ $100.00	High	i
9/5/2018	Benchmark	Reiterated Rating	Hold ➝ Hold		High	i
8/30/2018	The Goldman Sachs Group	Boost Price Target	Neutral	$75.00	Low	i
8/23/2018	Craig Hallum	Boost Price Target	Buy	$54.00 ➝ $74.00	Medium	i
8/23/2018	Jefferies Financial Group	Reiterated Rating	Buy	$74.00	High	i
8/23/2018	SVB Leerink	Reiterated Rating	Outperform	$90.00	High	i Rating by Puneet Souda at SVB Leerink LLC
8/23/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$65.00 ➝ $74.00	High	i
8/22/2018	BTIG Research	Boost Price Target	Buy	$95.00	High	i
8/13/2018	Canaccord Genuity	Reiterated Rating	Buy	$62.00 ➝ $65.00	Low	i
8/3/2018	Canaccord Genuity	Reiterated Rating	Buy	$62.00	Medium	i
8/2/2018	Jefferies Financial Group	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $57.00	High	i
8/2/2018	Bank of America	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $68.00	High	i Rating by Derik De Bruin at Bank of America Co.
8/2/2018	Craig Hallum	Lower Price Target	Buy	$60.00 ➝ $54.00	High	i
7/23/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$67.00 ➝ $75.00	Medium	i
7/18/2018	SVB Leerink	Reiterated Rating	Outperform ➝ Outperform	$67.00 ➝ $76.00	Low	i Rating by Puneet Souda at SVB Leerink LLC
7/9/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$66.00 ➝ $70.00	Low	i
6/18/2018	Cowen	Boost Price Target	Outperform	$65.00 ➝ $85.00	Low	i
6/15/2018	Canaccord Genuity	Boost Price Target	Buy	$70.00 ➝ $75.00	Medium	i
6/6/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$68.00 ➝ $70.00	Low	i
6/5/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$58.00 ➝ $66.00	Medium	i
6/5/2018	BTIG Research	Reiterated Rating	Buy		Medium	i
5/31/2018	Canaccord Genuity	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $68.00	Medium	i
5/30/2018	BTIG Research	Boost Price Target	Positive ➝ Buy	$60.00 ➝ $70.00	High	i
4/29/2018	BTIG Research	Reiterated Rating	Buy	$60.00	High	i
4/27/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$55.00 ➝ $60.00	High	i
4/3/2018	BTIG Research	Upgrade	Neutral ➝ Buy		Low	i
3/29/2018	William Blair	Reiterated Rating	Buy		N/A	i Rating by Brian Weinstein at William Blair
3/28/2018	SVB Leerink	Set Price Target	Buy	$67.00	High	i Rating by Puneet Souda at SVB Leerink LLC
2/27/2018	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$42.56 ➝ $56.00	Medium	i
2/23/2018	SVB Leerink	Set Price Target	Buy	$67.00	High	i Rating by Puneet Souda at SVB Leerink LLC
2/23/2018	Benchmark	Downgrade	Buy ➝ Hold		High	i Rating by Raymond Myers at Benchmark Co.
2/9/2018	SVB Leerink	Set Price Target	Buy	$67.00	Medium	i Rating by Puneet Souda at SVB Leerink LLC
1/29/2018	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$17.77 ➝ $51.00	Low	i
1/17/2018	Benchmark	Set Price Target	Buy	$65.00	Medium	i Rating by Raymond Myers at Benchmark Co.
1/10/2018	William Blair	Reiterated Rating	Buy		High	i Rating by Brian Weinstein at William Blair
1/8/2018	Bank of America	Set Price Target	Buy	$67.00	High	i Rating by Derik De Bruin at Bank of America Co.
1/2/2018	William Blair	Reiterated Rating	Buy		Low	i Rating by Brian Weinstein at William Blair
11/29/2017	Bank of America	Boost Price Target	Buy	$58.00 ➝ $67.00	Low	i Rating by Derik De Bruin at Bank of America Co.
11/13/2017	SVB Leerink	Reiterated Rating	Outperform	$63.00 ➝ $67.00	N/A	i Rating by Puneet Souda at SVB Leerink LLC
11/13/2017	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$56.00	N/A	i
11/1/2017	BTIG Research	Downgrade	Buy ➝ Neutral		N/A	i
10/31/2017	Bank of America	Boost Price Target	Buy	$56.00 ➝ $58.00	N/A	i Rating by Derik De Bruin at Bank of America Co.
10/31/2017	Canaccord Genuity	Upgrade	Buy	$60.00	N/A	i
10/31/2017	Robert W. Baird	Boost Price Target	Outperform	$49.00 ➝ $56.00	N/A	i
10/31/2017	Craig Hallum	Boost Price Target	Buy	$46.00 ➝ $61.00	N/A	i
10/31/2017	Benchmark	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $60.00	N/A	i Rating by Raymond Myers at Benchmark Co.
10/31/2017	SVB Leerink	Reiterated Rating	Outperform	$50.00 ➝ $63.00	N/A	i Rating by Puneet Souda at SVB Leerink LLC
10/31/2017	Jefferies Financial Group	Boost Price Target	Buy	$60.00	N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
10/19/2017	Bank of America	Set Price Target	Buy	$40.00 ➝ $56.00	N/A	i Rating by Derik De Bruin at Bank of America Co.
10/6/2017	Robert W. Baird	Reiterated Rating	Buy	$49.00	N/A	i
10/3/2017	Canaccord Genuity	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $60.00	High	i
9/21/2017	SVB Leerink	Reiterated Rating	Outperform ➝ Outperform	$45.00 ➝ $50.00	High	i Rating by Puneet Souda at SVB Leerink LLC
9/7/2017	Canaccord Genuity	Reiterated Rating	Buy	$45.00	Low	i
8/24/2017	SVB Leerink	Set Price Target	Buy	$45.00	Medium	i Rating by Puneet Souda at SVB Leerink LLC
7/26/2017	Canaccord Genuity	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $45.00	High	i
7/26/2017	Bank of America	Reiterated Rating	Buy		High	i
7/26/2017	Roth Capital	Boost Price Target	Buy	$40.00 ➝ $46.00	High	i Rating by C. Lewis at Roth Capital
7/26/2017	Craig Hallum	Reiterated Rating	Buy	$41.00 ➝ $46.00	High	i Rating by William Bonello at Craig Hallum
7/26/2017	Lake Street Capital	Boost Price Target	Hold ➝ Hold	$30.00 ➝ $41.00	Medium	i
7/20/2017	Canaccord Genuity	Reiterated Rating	Buy	$38.00 ➝ $42.00	Medium	i Rating by Mark Massaro at Canaccord Genuity
7/17/2017	BTIG Research	Reiterated Rating	Buy	$35.00 ➝ $45.00	Low	i
7/7/2017	Benchmark	Set Price Target	Buy	$50.00	Low	i Rating by Raymond Myers at Benchmark Co.
7/7/2017	Craig Hallum	Boost Price Target		$35.00 ➝ $41.00	High	i Rating by William Bonello at Craig Hallum
6/12/2017	Bank of America	Reiterated Rating	Buy	$34.00 ➝ $38.00	Low	i
6/9/2017	Canaccord Genuity	Lower Price Target	Buy	$40.00 ➝ $38.00	Low	i Rating by Mark Massaro at Canaccord Genuity
6/7/2017	Stephens	Set Price Target	Hold	$28.00	Medium	i Rating by Drew Jones at Stephens
6/1/2017	Roth Capital	Reiterated Rating	Buy	$33.00 ➝ $40.00	Low	i Rating by C. Lewis at Roth Capital
6/1/2017	Robert W. Baird	Reiterated Rating	Outperform	$40.00	Low	i Rating by Catherine W. Ramsey at Robert W. Baird
6/1/2017	Jefferies Financial Group	Set Price Target	Buy	$35.00	Medium	i Rating by Biren Amin at Jefferies Financial Group Inc.
5/31/2017	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $40.00	High	i Rating by Mark Massaro at Canaccord Genuity
5/31/2017	Cowen	Reiterated Rating	Outperform	$45.00	High	i
5/31/2017	Benchmark	Boost Price Target	Buy ➝ Buy	$34.00 ➝ $50.00	High	i
5/16/2017	Jefferies Financial Group	Reiterated Rating	Buy	$35.00	Low	i
5/15/2017	Cowen	Boost Price Target	Outperform	$40.00 ➝ $45.00	N/A	i
5/5/2017	Cowen	Boost Price Target	Outperform	$40.00 ➝ $45.00	Low	i
5/1/2017	The Goldman Sachs Group	Set Price Target	Neutral	$21.00 ➝ $33.00	Medium	i
4/28/2017	SVB Leerink	Set Price Target	Buy	$38.00	Medium	i Rating by Puneet Souda at SVB Leerink LLC
4/27/2017	Cowen	Boost Price Target	Outperform ➝ Outperform	$30.00 ➝ $40.00	Low	i
4/26/2017	Jefferies Financial Group	Reiterated Rating	Buy	$25.00	High	i
4/24/2017	Canaccord Genuity	Reiterated Rating	Buy	$27.00	Low	i Rating by Mark Massaro at Canaccord Genuity
4/17/2017	SVB Leerink	Initiated Coverage	Outperform ➝ Outperform	$30.00	Low	i Rating by P. Souda at SVB Leerink LLC
4/4/2017	Cowen	Reiterated Rating	Outperform	$30.00	Low	i
3/29/2017	Bank of America	Reiterated Rating	Buy		High	i
3/27/2017	Craig Hallum	Set Price Target	Buy	$28.00	High	i Rating by William Bonello at Craig Hallum
3/27/2017	Cowen	Initiated Coverage	Outperform	$30.00	High	i
2/22/2017	Canaccord Genuity	Reiterated Rating	Buy	$27.00 ➝ $24.00	N/A	i Rating by Mark Massaro at Canaccord Genuity
2/22/2017	Roth Capital	Upgrade	Neutral ➝ Buy	$15.00 ➝ $26.00	N/A	i Rating by C. Lewis at Roth Capital
2/21/2017	Benchmark	Upgrade	Hold ➝ Buy	$17.00 ➝ $27.00	N/A	i
1/31/2017	Craig Hallum	Set Price Target	Buy	$26.00	N/A	i Rating by William Bonello at Craig Hallum
1/23/2017	Canaccord Genuity	Set Price Target	Buy	$24.00	N/A	i Rating by Mark Massaro at Canaccord Genuity
1/9/2017	Canaccord Genuity	Set Price Target	Buy	$24.00	N/A	i Rating by Mark Massaro at Canaccord Genuity
1/8/2017	BTIG Research	Reiterated Rating	Buy	$22.00	N/A	i
12/20/2016	Robert W. Baird	Set Price Target	Buy	$22.00	N/A	i Rating by Catherine W. Ramsey at Robert W. Baird
12/13/2016	Canaccord Genuity	Set Price Target	Buy	$24.00	N/A	i Rating by Mark Massaro at Canaccord Genuity
11/9/2016	Canaccord Genuity	Set Price Target	Buy	$24.00	N/A	i Rating by Mark Massaro at Canaccord Genuity
11/1/2016	Lake Street Capital	Lower Price Target	Hold	$15.00 ➝ $8.00	N/A	i
10/28/2016	Canaccord Genuity	Reiterated Rating	Buy	$24.00	N/A	i Rating by Mark Massaro at Canaccord Genuity
10/26/2016	Benchmark	Boost Price Target	Hold	$14.00 ➝ $17.00	N/A	i
10/4/2016	Jefferies Financial Group	Boost Price Target	Buy	$20.00 ➝ $23.00	N/A	i Rating by Brandon Couillard at Jefferies Financial Group Inc.
9/4/2016	Craig Hallum	Set Price Target	Buy	$26.00	N/A	i Rating by william bonello at Craig Hallum
8/15/2016	The Goldman Sachs Group	Boost Price Target	Neutral	$16.00 ➝ $18.00	N/A	i
8/1/2016	Roth Capital	Reiterated Rating	Hold	$11.00 ➝ $15.00	N/A	i Rating by Chris Lewis at Roth Capital
7/31/2016	Robert W. Baird	Reiterated Rating	Outperform	$18.00	N/A	i
7/31/2016	BTIG Research	Reiterated Rating	Buy	$20.00	N/A	i Rating by Sean Lavin at BTIG Research
7/27/2016	Craig Hallum	Boost Price Target	Buy	$18.00 ➝ $26.00	N/A	i Rating by William Bonello at Craig Hallum
7/27/2016	Jefferies Financial Group	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $20.00	N/A	i Rating by Brandon Couillard at Jefferies Financial Group Inc.
7/27/2016	Benchmark	Lower Price Target	Hold	$14.00 ➝ $9.00	N/A	i Rating by Jan Wald at Benchmark Co.
7/27/2016	Mizuho	Boost Price Target	Neutral	$10.00 ➝ $15.00	N/A	i Rating by Eric Criscuolo at Mizuho
7/26/2016	Canaccord Genuity	Reiterated Rating	Buy		N/A	i Rating by Mark Massaro at Canaccord Genuity
7/15/2016	William Blair	Reiterated Rating	Outperform	$29.00	N/A	i Rating by Brian Weinstein at William Blair
6/22/2016	Craig Hallum	Reiterated Rating	Buy		N/A	i Rating by William Bonello at Craig Hallum
6/22/2016	Robert W. Baird	Reiterated Rating	Outperform	$12.00 ➝ $15.00	N/A	i
6/16/2016	Craig Hallum	Upgrade	Hold ➝ Buy	$6.00 ➝ $18.00	N/A	i Rating by William Bonello at Craig Hallum
6/15/2016	William Blair	Reiterated Rating	Buy		N/A	i Rating by Brian Weinstein at William Blair
6/15/2016	Roth Capital	Reiterated Rating	Hold	$7.00 ➝ $7.00	N/A	i Rating by Chris Lewis at Roth Capital
6/15/2016	Jefferies Financial Group	Reiterated Rating	Buy	$13.00	N/A	i Rating by Brandon Couillard at Jefferies Financial Group Inc.
6/15/2016	Canaccord Genuity	Reiterated Rating	Buy	$9.00 ➝ $12.00	N/A	i Rating by Mark Massaro at Canaccord Genuity
6/15/2016	Mizuho	Reiterated Rating	Hold	$6.50	N/A	i Rating by Eric Criscuolo at Mizuho
6/15/2016	BTIG Research	Reiterated Rating	Buy	$9.00	N/A	i Rating by Sean Lavin at BTIG Research
5/24/2016	BTIG Research	Reiterated Rating	Buy	$9.00	N/A	i Rating by Sean Lavin at BTIG Research
5/10/2016	BTIG Research	Reiterated Rating	Buy		N/A	i Rating by Sean Lavin at BTIG Research
5/4/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by Brandon Couillard at Jefferies Financial Group Inc.
5/4/2016	Mizuho	Downgrade	Buy ➝ Neutral	$12.00 ➝ $6.50	N/A	i
5/2/2016	Canaccord Genuity	Reiterated Rating	Buy	$9.00	N/A	i Rating by Mark Massaro at Canaccord Genuity
3/1/2016	BTIG Research	Reiterated Rating	Buy	$9.00	N/A	i Rating by Sean Lavin at BTIG Research
2/26/2016	The Goldman Sachs Group	Lower Price Target	Neutral	$8.00 ➝ $7.00	N/A	i Rating by Isaac Ro at The Goldman Sachs Group, Inc.
2/25/2016	Canaccord Genuity	Lower Price Target	Buy	$13.00 ➝ $9.00	N/A	i Rating by Mark Massaro at Canaccord Genuity
2/25/2016	Stephens	Downgrade	Overweight ➝ Equal Weight		N/A	i Rating by Drew Jones at Stephens
2/25/2016	Jefferies Financial Group	Lower Price Target	Buy	$15.00 ➝ $13.00	N/A	i Rating by Brandon Couillard at Jefferies Financial Group Inc.
2/25/2016	Roth Capital	Downgrade	Buy ➝ Neutral		N/A	i Rating by Chris Lewis at Roth Capital
2/24/2016	Benchmark	Reiterated Rating	Hold	$11.00 ➝ $9.00	N/A	i Rating by Jan Wald at Benchmark Co.
2/24/2016	Craig Hallum	Downgrade	Buy ➝ Hold	$22.00 ➝ $6.00	N/A	i Rating by William Bonello at Craig Hallum

(Data available from 2/24/2016 forward)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Today's Range

Now: $134.82

$133.54

$140.69

50 Day Range

MA: $143.99

$124.28

$155.01

52 Week Range

Now: $134.82

$35.25

$159.54

Volume

1,847,669 shs

Average Volume

1,925,685 shs

Market Capitalization

$22.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Exact Sciences?

The following Wall Street analysts have issued reports on Exact Sciences in the last year: Bank of America Co., Benchmark Co., BTIG Research, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Craig Hallum, Evercore ISI, Oppenheimer Holdings Inc., Robert W. Baird, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, TheStreet, Truist, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for EXAS.

What is the current price target for Exact Sciences?

16 Wall Street analysts have set twelve-month price targets for Exact Sciences in the last year. Their average twelve-month price target is $145.31, suggesting a possible upside of 4.8%. Truist has the highest price target set, predicting EXAS will reach $226.00 in the next twelve months. Evercore ISI has the lowest price target set, forecasting a price of $70.00 for Exact Sciences in the next year.
View the latest price targets for EXAS.

What is the current consensus analyst rating for Exact Sciences?

Exact Sciences currently has 3 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EXAS will outperform the market and that investors should add to their positions of Exact Sciences.
View the latest ratings for EXAS.

What other companies compete with Exact Sciences?

Other companies that are similar to Exact Sciences include Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Biogen, Alexion Pharmaceuticals, Seagen, Alnylam Pharmaceuticals, Incyte, Novavax, BioMarin Pharmaceutical, Repligen, Neurocrine Biosciences, Ionis Pharmaceuticals and United Therapeutics.

How do I contact Exact Sciences' investor relations team?

Exact Sciences' physical mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company's listed phone number is 608-535-8815 and its investor relations email address is [email protected] The official website for Exact Sciences is www.exactsciences.com.

NASDAQ:EXAS - Exact Sciences Stock Price Target and Predictions

Analyst Price Target for EXAS

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Exact Sciences?

What is the current price target for Exact Sciences?

What is the current consensus analyst rating for Exact Sciences?

What other companies compete with Exact Sciences?

How do I contact Exact Sciences' investor relations team?